Natus Medical Inc.

Find Ratings Reports
BABY : NASDAQ : Health Technology
$33.35 | %
Today's Range: 32.7 - 33.45
Avg. Daily Volume: 516100.0
03/16/18 - 4:00 PM ET

Financial Analysis

NATUS MEDICAL INC's gross profit margin for the fourth quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. NATUS MEDICAL INC is extremely liquid. Currently, the Quick Ratio is 2.34 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

At the same time, stockholders' equity ("net worth") has remained virtually unchanged only increasing by 1.13% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit

Income Statement Q4 FY17 Q4 FY16
Net Sales ($mil)131.44107.7
EBITDA ($mil)20.4423.59
EBIT ($mil)11.219.53
Net Income ($mil)-7.110.23

Balance Sheet Q4 FY17 Q4 FY16
Cash & Equiv. ($mil)88.95247.57
Total Assets ($mil)709.92649.01
Total Debt ($mil)154.28140.0
Equity ($mil)422.1417.37

Profitability Q4 FY17 Q4 FY16
Gross Profit Margin59.8862.56
EBITDA Margin15.5521.9
Operating Margin8.5218.13
Sales Turnover0.710.59
Return on Assets-2.856.56
Return on Equity-4.810.2
Debt Q4 FY17 Q4 FY16
Current Ratio3.325.08
Interest Expense0.00.08
Interest Coverage0.0247.2

Share Data Q4 FY17 Q4 FY16
Shares outstanding (mil)33.1532.92
Div / share0.00.0
Book value / share12.7312.68
Institutional Own % n/a n/a
Avg Daily Volume532604.0371765.0


HOLD. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 2.58 indicates a discount versus the S&P 500 average of 3.28 and a significant discount versus the industry average of 5.73. The price-to-sales ratio is below the S&P 500 average and is well below the industry average, indicating a discount. After reviewing these and other key valuation criteria, NATUS MEDICAL INC proves to trade at a discount to investment alternatives within the industry.

1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
BABY NM Peers 115.38   BABY NA Peers 46.03

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

BABY's P/E is negative making this valuation measure meaningless.


Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.

Ratio not available.

1 2 3 4 5
premium   discount
  Price to
1 2 3 4 5
premium   discount
BABY 17.88 Peers 32.67   BABY NA Peers 0.78

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

BABY is trading at a significant discount to its peers.


Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
BABY 2.58 Peers 5.73   BABY -148.06 Peers 3.03

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

BABY is trading at a significant discount to its peers.


Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, BABY is expected to significantly trail its peers on the basis of its earnings growth rate.

1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
BABY 2.18 Peers 6.04   BABY 31.18 Peers 17.05

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

BABY is trading at a significant discount to its industry on this measurement.


Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

BABY has a sales growth rate that significantly exceeds its peers.



Latest Stock Upgrades/Downgrades